TapewireFind a company

person · Reporting owner

Tanguler Tolga

Disclosed activity across 2 companies

Tapewire entity
34717
SEC CIK
0001849458

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132EVP, Chief Commercial OfficerMarch 04, 2026March 06, 2026
Lexeo Therapeutics, Inc.LXEO · Entity 5687DirectorJune 25, 2026June 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date March 04, 2026 · Filed March 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect34,297 Ending reported balance After 2026-03-04 transaction · row 8
8 source rows · reconciled sequence

Row 1 · 2026-03-04 · Sale · Disposed 106 · Balance 36,500

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 2 · 2026-03-04 · Sale · Disposed 102 · Balance 36,398

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 3 · 2026-03-04 · Sale · Disposed 215 · Balance 36,183

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 4 · 2026-03-04 · Sale · Disposed 289 · Balance 35,894

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 5 · 2026-03-04 · Sale · Disposed 350 · Balance 35,544

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 6 · 2026-03-04 · Sale · Disposed 767 · Balance 34,777

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 7 · 2026-03-04 · Sale · Disposed 272 · Balance 34,505

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 8 · 2026-03-04 · Sale · Disposed 208 · Balance 34,297

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Lexeo Therapeutics, Inc.

Report date June 25, 2026 · Filed June 29, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2036-06-24Direct35,000 Reported balance After 2026-06-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-25 · Grant · Acquired 35,000 · Balance 35,000

F1: 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 11, 2024 Filed Nov 13, 2024 22:34 UTC Lexeo Therapeutics, Inc. LXEO · Entity 5687 GrantStock Option (right to buy) · Derivative 36,000 $0.00 Strike: $7.95 $0.00
Disclosure

SEC source: 0001415889-24-026739 · form4-11132024_101138.xml · derivative · entry 1

Tanguler Tolga · CIK 0001849458 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2034-11-10

F1 · derivative.exercise_date: The shares subject to the option shall vest and become exercisable in equal annual installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service.

Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 167 $235.19 $39,276.73
Disclosure

SEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 13

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,660

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $235.10 to $235.73. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 185 $234.66 $43,412.10
Disclosure

SEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 12

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,827

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $234.06 to $235.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 115 $233.53 $26,855.95
Disclosure

SEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 11

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,012

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $233.00 to $234.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 216 $232.54 $50,228.64
Disclosure

SEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 10

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,127

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $231.97 to $232.97. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 99 $231.59 $22,927.41
Disclosure

SEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 9

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,343

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $230.92 to $231.78. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 304 $229.93 $69,898.72
Disclosure

SEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 8

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,442

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $229.76 to $230.70. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 266 $229.06 $60,929.96
Disclosure

SEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 7

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,746

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $228.75 to $229.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 129 $228.30 $29,450.70
Disclosure

SEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 6

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,012

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $227.72 to $228.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 34 $226.82 $7,711.88
Disclosure

SEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 5

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,141

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $226.45 to $227.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 18 $225.55 $4,059.90
Disclosure

SEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 4

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,175

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $224.99 to $225.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 13 $224.17 $2,914.21
Disclosure

SEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 3

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,193

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $223.92 to $224.43. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 25, 2024 Filed Jun 26, 2024 20:26 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 59 $221.71 $13,080.89
Disclosure

SEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 2

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,206

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $221.37 to $222.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 20:26 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantCommon Stock 3,278 $0.00 $0.00
Disclosure

SEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 1

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,265

F1 · kind: On February 23, 2022, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 clinical study in ATTR amyloidosis with cardiomyopathy, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on June 24, 2024.

Read SEC document
March 01, 2024 Filed Mar 5, 2024 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 9,279 $0.00 Strike: $152.61 $0.00
Disclosure

SEC source: 0001735276-24-000030 · edgardoc.xml · derivative · entry 2

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,279

Underlying: Common Stock · 9,279 shares

Expires 2034-03-01

F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vesting in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.

Read SEC document
March 01, 2024 Filed Mar 5, 2024 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantCommon Stock 4,751 $0.00 $0.00
Disclosure

SEC source: 0001735276-24-000030 · edgardoc.xml · nonDerivative · entry 1

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,987

F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.

F2 · balance_after: The Reporting Person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 4,751 newly awarded RSUs and 5,236 shares of common stock. The Reporting Person also holds 3,333 unvested RSUs that were previously reported in Table II.

Read SEC document
February 28, 2024 Filed Feb 29, 2024 21:18 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 1 $158.09 $158.09
Disclosure

SEC source: 0001735276-24-000020 · edgardoc.xml · nonDerivative · entry 6

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,236

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

Read SEC document
February 28, 2024 Filed Feb 29, 2024 21:18 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 14 $157.30 $2,202.20
Disclosure

SEC source: 0001735276-24-000020 · edgardoc.xml · nonDerivative · entry 5

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,237

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $157.01 to $157.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2024 Filed Feb 29, 2024 21:18 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 100 $156.38 $15,638.00
Disclosure

SEC source: 0001735276-24-000020 · edgardoc.xml · nonDerivative · entry 4

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,251

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $155.96 to $156.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2024 Filed Feb 29, 2024 21:18 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 170 $155.45 $26,426.50
Disclosure

SEC source: 0001735276-24-000020 · edgardoc.xml · nonDerivative · entry 3

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,351

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.95 to $155.95. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2024 Filed Feb 29, 2024 21:18 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 216 $154.54 $33,380.64
Disclosure

SEC source: 0001735276-24-000020 · edgardoc.xml · nonDerivative · entry 2

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,521

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.94 to $154.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 27, 2024 Filed Feb 29, 2024 21:18 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionRestricted Stock Units · Derivative 1,667 $0.00 $0.00
Disclosure

SEC source: 0001735276-24-000020 · edgardoc.xml · derivative · entry 7

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,333

Underlying: Common Stock · 1,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.

F7 · derivative.exercise_date: On February 27, 2023, the reporting person was granted 5,000 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.

F7 · derivative.expiration_date: On February 27, 2023, the reporting person was granted 5,000 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.

Read SEC document
February 27, 2024 Filed Feb 29, 2024 21:18 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 1,667 $0.00 $0.00
Disclosure

SEC source: 0001735276-24-000020 · edgardoc.xml · nonDerivative · entry 1

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,737

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 16, 2024 Filed Feb 20, 2024 21:08 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 121 $149.03 $18,032.63
Disclosure

SEC source: 0001735276-24-000008 · edgardoc.xml · nonDerivative · entry 4

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,070

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $148.96 to $149.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 16, 2024 Filed Feb 20, 2024 21:08 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 519 $148.24 $76,936.56
Disclosure

SEC source: 0001735276-24-000008 · edgardoc.xml · nonDerivative · entry 3

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,191

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $147.88 to $148.83. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 16, 2024 Filed Feb 20, 2024 21:08 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 369 $147.50 $54,427.50
Disclosure

SEC source: 0001735276-24-000008 · edgardoc.xml · nonDerivative · entry 2

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,710

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $146.88 to $147.87. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 15, 2024 Filed Feb 20, 2024 21:08 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantCommon Stock 3,278 $0.00 $0.00
Disclosure

SEC source: 0001735276-24-000008 · edgardoc.xml · nonDerivative · entry 1

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,079

F1 · kind: On February 23, 2022, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting $1.5 billion in total annual revenue, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on February 15, 2024.

Read SEC document
April 27, 2023 Filed Apr 28, 2023 21:55 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 103 $197.08 $20,299.24
Disclosure

SEC source: 0001735276-23-000046 · edgardoc.xml · nonDerivative · entry 6

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,801

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

Read SEC document
April 27, 2023 Filed Apr 28, 2023 21:55 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 64 $195.65 $12,521.60
Disclosure

SEC source: 0001735276-23-000046 · edgardoc.xml · nonDerivative · entry 5

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,904

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 195.50 to $196.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
April 27, 2023 Filed Apr 28, 2023 21:55 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 625 $194.94 $121,837.50
Disclosure

SEC source: 0001735276-23-000046 · edgardoc.xml · nonDerivative · entry 4

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,968

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 194.49 to $195.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
April 27, 2023 Filed Apr 28, 2023 21:55 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 562 $193.93 $108,988.66
Disclosure

SEC source: 0001735276-23-000046 · edgardoc.xml · nonDerivative · entry 3

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,593

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 193.48 to $194.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
April 27, 2023 Filed Apr 28, 2023 21:55 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 122 $193.18 $23,567.96
Disclosure

SEC source: 0001735276-23-000046 · edgardoc.xml · nonDerivative · entry 2

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,155

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 192.47 to $193.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
April 26, 2023 Filed Apr 28, 2023 21:55 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantCommon Stock 3,277 $0.00 $0.00
Disclosure

SEC source: 0001735276-23-000046 · edgardoc.xml · nonDerivative · entry 1

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,277

F1 · kind: On February 23, 2022, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2021 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of human proof-of-concept of an investigational therapeutic directed to an extrahepatic target (central nervous system, or CNS).

Read SEC document
February 27, 2023 Filed Mar 1, 2023 21:21 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 10,352 $0.00 Strike: $190.01 $0.00
Disclosure

SEC source: 0001735276-23-000027 · edgardoc.xml · derivative · entry 2

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,352

Underlying: Common Stock · 10,352 shares

Expires 2033-02-27

F4 · shares: Represents the time-vested stock option portion of the reporting person's annual equity award granted in 2023 for 2022 performance.

F5 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares at the end of each successive three month period thereafter until the fourth anniversary of the grant date.

Read SEC document
February 27, 2023 Filed Mar 1, 2023 21:21 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantRestricted Stock Units · Derivative 5,000 $0.00 $0.00
Disclosure

SEC source: 0001735276-23-000027 · edgardoc.xml · derivative · entry 1

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2026-02-27

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.

F2 · shares: Represents the time-vested restricted stock unit portion of the reporting person's annual equity award granted in 2023 for 2022 performance. The reporting person also received 10,000 performance stock units as part of their annual equity award that will vest upon the achievement of three specific performance conditions (subject to a one year minimum vesting period), which will be reported on a Form 4 as to the performance stock units allocated to each performance condition if and when each performance condition is met and the performance stock units vest.

F3 · derivative.exercise_date: The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date.

F3 · derivative.expiration_date: The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date.

Read SEC document
February 03, 2023 Filed Feb 3, 2023 22:45 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 953 $233.31 $222,344.43
Disclosure

SEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 10

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F5 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022.

F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $233.02 to $233.81. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 03, 2023 Filed Feb 3, 2023 22:45 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 1,293 $232.53 $300,661.29
Disclosure

SEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 9

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 953

F5 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022.

F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $231.94 to $232.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 03, 2023 Filed Feb 3, 2023 22:45 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 865 $231.35 $200,117.75
Disclosure

SEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 8

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,246

F5 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022.

F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $230.90 to $231.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 03, 2023 Filed Feb 3, 2023 22:45 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 185 $230.20 $42,587.00
Disclosure

SEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 7

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,111

F5 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $229.87 to $230.62. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 03, 2023 Filed Feb 3, 2023 22:45 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 128 $227.68 $29,143.04
Disclosure

SEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 6

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,296

F5 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $227.63 to $228.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 02, 2023 Filed Feb 3, 2023 22:45 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 4 $227.38 $909.52
Disclosure

SEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 5

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,424

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

Read SEC document
February 02, 2023 Filed Feb 3, 2023 22:45 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 561 $226.62 $127,133.82
Disclosure

SEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 4

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,428

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $226.23 to $227.12. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 02, 2023 Filed Feb 3, 2023 22:45 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 963 $225.80 $217,445.40
Disclosure

SEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 3

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,989

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $225.21 to $226.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 02, 2023 Filed Feb 3, 2023 22:45 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 73 $223.97 $16,349.81
Disclosure

SEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 2

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,952

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $223.42 to $224.25. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 01, 2023 Filed Feb 3, 2023 22:45 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionRestricted Stock Units · Derivative 5,025 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001735276-23-000006 · edgardoc.xml · derivative · entry 11

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,025 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.

F12 · derivative.exercise_date: On February 1, 2021 the reporting person received 10,051 restricted stock units, one-half of which vested on the first anniversary of the grant date, and one-half of which vested on the second anniversary of the grant date (February 1, 2023).

F12 · derivative.expiration_date: On February 1, 2021 the reporting person received 10,051 restricted stock units, one-half of which vested on the first anniversary of the grant date, and one-half of which vested on the second anniversary of the grant date (February 1, 2023).

Read SEC document
February 01, 2023 Filed Feb 3, 2023 22:45 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 5,025 $0.00 $0.00
Disclosure

SEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 1

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,025

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 05, 2022 Filed Aug 5, 2022 20:15 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 104 $225.15 $23,415.60
Disclosure

SEC source: 0001735276-22-000067 · edgardoc.xml · nonDerivative · entry 12

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022.

Read SEC document
August 05, 2022 Filed Aug 5, 2022 20:15 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 5 $224.00 $1,120.00
Disclosure

SEC source: 0001735276-22-000067 · edgardoc.xml · nonDerivative · entry 11

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104

F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022.

Read SEC document
August 05, 2022 Filed Aug 5, 2022 20:15 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 105 $220.95 $23,199.75
Disclosure

SEC source: 0001735276-22-000067 · edgardoc.xml · nonDerivative · entry 10

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109

F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022.

Read SEC document
August 05, 2022 Filed Aug 5, 2022 20:15 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 99 $219.53 $21,733.47
Disclosure

SEC source: 0001735276-22-000067 · edgardoc.xml · nonDerivative · entry 9

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214

F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.